Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
PR Newswire•19/10/2026•07:00 ET
0
Key Highlights
- ➤BRINSUPRI launches in Japan for adults and pediatric patients 12 years and older
- ➤BRINSUPRI is Japan’s first approved and commercially available NCFB treatment
- ➤Japan’s MHLW approved BRINSUPRI in August 2026 based on Phase 3 ASPEN results
- ➤BRINSUPRI is an oral, once-daily 25 mg treatment for NCFB
Expert Statements
Samuele Butera, Senior Vice President, General Manager, Global Respiratory at Insmed
“The commercial availability of BRINSUPRI in Japan is a meaningful step forward for the bronchiectasis community and a proud moment for our team”
Samuele Butera, Senior Vice President, General Manager, Global Respiratory at Insmed
“As the first approved therapy specifically designed to address the underlying inflammatory process of NCFB, we are pleased that BRINSUPRI can be made widely available to appropriate patients in Japan who have long needed a treatment option that addresses an unmet driver of their disease.”
Makoto Nakamura, Senior Vice President, General Manager, Japan at Insmed
“In patients living with bronchiectasis, recurrent exacerbations represent a substantial disease burden, making daily life harder to manage and affecting long-term clinical outcomes”
Makoto Nakamura, Senior Vice President, General Manager, Japan at Insmed
“By offering BRINSUPRI as a new treatment option for appropriate patients in Japan, we hope to contribute to better disease management for eligible patients. Insmed remains committed to supporting the bronchiectasis community through appropriate information provision to healthcare professionals and advancing the proper use of this therapy.”
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan PR Newswire
—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan—
Get started
Create a free account to read the full story.